SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Consideration of Approval of Transfer of License and Conforming Amendment

The U.S. Nuclear Regulatory Commission (NRC, the Commission) received and is considering approval of an application filed by Illuminated Holdings, Inc. and its wholly owned subsidiary, SHINE Technologies, LLC, on February 4, 2026. The application seeks NRC approval of the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility, currently held by SHINE Technologies, LLC (the current licensee) to a newly formed company, SHINE Chrysalis, LLC, and issuance of a conforming license amendment. The application also seeks NRC approval of the indirect transfer of control of the construction permit as a result of the establishment of a new intermediate parent company, SHINE Chrysalis Holdings, LLC, which will be the direct corporate parent of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a direct subsidiary of Illuminated Holdings, Inc. The application contains sensitive unclassified non-safeguards information (SUNSI).